welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Myocardial Involvement in Carriers of Duchenne Muscular Dystrophy: An MRI-study
study id #: NCT01712152
condition: Carrier of Duchenne Muscular Dystrophy
Carriers of Duchenne muscular dystrophy (DMD) often have no severe symptoms of the scelet muscles, but they may develop a poor heart function due to the involvement of the heart muscle. Ultrasound of the heart is recommended, but it can detect a cardiac affection only after the heart has already become weaker. Cardiac magnetic resonance tomography can detect myocardial fibrosis already at preserved heart function and may facilitate early therapy. In our study, diagnosed carriers of DMD will undergo examinations of the heart by blood tests, EKG, heart ultrasound and magnetic resonance at enrollment and after one year in order to assess the extent of cardiac affection and its association with the clinical development.
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: October 2012
estimated completion: April 2014
size / enrollment: 20
- T1 mapping [ Time Frame: 1 year ]
T1 mapping by MOLLI sequences will be performed and compared between study entry and one year follow-up
- left ventricular function [ Time Frame: 1 year ]
left ventricular function on MRI will be compared between study entry and one year follow-up
genetic and/or histological identification as a carrier of DMD age above 18 years able and willing to conform to the requirements of the study provided written informed consent exclusion of pregnancy in women of childbearing potential
Claustrophobia Excessive obesity to an extent where CMR cannot be performed Chronic renal failure with a GFR <30 ml/min/1,73m² Implanted pacemakers/defibrillators Severe arrhythmia Inability to cooperate during the CMR Known intolerance to gadolinium Positive pregnancy test Unable or unwilling to conform to the study protocol
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
A Device for Rapid, Painless, Bedside Muscle Evaluation of ChildrenThe purpose of this protocol is to perfo...
Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrop...To Assess the Activity and Safety of SMT...
Stacking Exercises Aid the Decline in FVC and Sick TimeDuchenne Muscular Dystrophy is complicat...
Magnetic Resonance Imaging and Biomarkers for Muscular DystrophyThe purpose of this research study is to...
A Study of TAS-205 for Duchenne Muscular DystrophyThe objective of this study is to evalua...
Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)The primary objective of this Expanded A...
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
DuchenneXchange Clinical Trial Finder LaunchesThe DuchenneXchange Clinical Trial Finde...
Design of a phase 3 trial to evaluate the long-term efficacy and safety of ataluren in patients with nonsense mutati...Ataluren is conditionally approved by th...
Clay Matthews Supports Duchenne Muscular Dystrophy and First Approved Treatmenthttps://www.youtube.com/watch?v=WPu5pGEF...
Diagnosed with Duchenne – Embracing Life Beyond the DevastationThe Beautiful Blessings of Motherhood I...